Table 3.
Efficacy of checkpoint-inhibitor plus denosumab treatment in certain subgroups
| BRAF V600E-mutation (N = 17) | BRAF V600E wild type (N = 12) | Total (N = 29) | |
|---|---|---|---|
| Best overall response: no. (%) | |||
| Complete response | 1 (6%) | 4 (33%) | 5 (17%) |
| Partial response | 7 (41%) | 3 (25%) | 10 (34%) |
| Stable disease | 5 (29%) | 2 (17%) | 7 (24%) |
| Progressive disease | 4 (24%) | 3 (25%) | 7 (24%) |
| Objective response: no. (%) | 8 (47%) | 7 (58%) | |
| Elevated LDH level (N = 15) | Normal LDH level (N = 14) | Total (N = 29) | |
| Best overall response: no. (%) | |||
| Complete response | 2 (13%) | 3 (21%) | 5 (17%) |
| Partial response | 7 (47%) | 3 (21%) | 10 (34%) |
| Stable disease | 2 (13%) | 5 (36%) | 7 (24%) |
| Progressive disease | 4 (27%) | 3 (21%) | 7 (24%) |
| Objective response: no. (%) | 9 (60%) | 6 (43%) | |
| M1c (N = 20) | M1d (N = 9) | Total (N = 29) | |
| Best overall response: no. (%) | |||
| Complete response | 4 (20%) | 1(11%) | 5 (17%) |
| Partial response | 7 (35%) | 3 (33%) | 10 (34%) |
| Stable disease | 7 (35%) | 0 (0%) | 7 (24%) |
| Progressive disease | 2 (10%) | 5 (56%) | 7 (24%) |
| Objective response: no. (%) | 11 (55%) | 4 (44%) | |